Raymond James last night initiated coverage of INmune Bio with an Outperform rating and $18 price target. The company’s lead program XPro is a novel approach for treating early Alzheimer’s by targeting neuroinflammation in the brain with strong scientific rationale, the analyst tells investors in a research note. The firm is optimistic the company’s XPro’s Phase 2 data, expected in Q2 of 2025, will be positive. Early Alzheimer’s represents significant opportunity for XPro, with further optionality in autoimmune conditions, contends Raymond James.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio initiated with an Outperform at Raymond James
- INmune announces initial results from Phase I/II trial of INKmune with mCRPC
- INmune Bio announces results of additional interim analysis of Phase 2 trial
- INmune Bio initiated with an Outperform at Scotiabank on Alzheimer’s potential
- Scotiabank starts INmune with Outperform on Alzheimer’s potential